J9347 Injection, tremelimumab-actl, 1 milligrams
Also known as: tremelimumab, Imjudo
Injection of tremelimumab-actl, 1 milligram. A cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) checkpoint inhibitor monoclonal antibody.
In Plain Language
immunotherapy injection; cancer immune checkpoint drug
Clinical Context
Used for hepatocellular carcinoma with durvalumab (PD-L1 inhibitor). CTLA-4 blockade enhances T-cell activation.
RVU Information
CPT J9347 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9347?
CPT J9347 (Injection, tremelimumab-actl, 1 milligrams) is a J Codes (Drugs) code. Injection of tremelimumab-actl, 1 milligram. A cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) checkpoint inhibitor monoclonal antibody.
How is J9347 administered?
CPT J9347 is administered by a healthcare provider, typically via injection or infusion. Used for hepatocellular carcinoma with durvalumab (PD-L1 inhibitor). CTLA-4 blockade enhances T-cell activation. It is used by Oncology, Gastroenterology, Hepatology.
When is CPT J9347 used?
Used for hepatocellular carcinoma with durvalumab (PD-L1 inhibitor). CTLA-4 blockade enhances T-cell activation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.